D
Aligos Therapeutics, Inc.
ALGS
$5.23
-$1.25-19.29%
D
Sell
12/20/2024Upgraded
Aligos Therapeutics, Inc. (ALGS) was upgraded to D- from E+ on 12/20/2024 due to an increase in the volatility index and total return index.
Aligos Therapeutics, Inc. (ALGS) was upgraded to D- from E+ on 12/20/2024 due to an increase in the volatility index and total return index.
E
Sell
9/24/2024Downgrade
Aligos Therapeutics, Inc. (ALGS) was downgraded to E+ from D- on 9/24/2024 due to a decline in the volatility index.
Aligos Therapeutics, Inc. (ALGS) was downgraded to E+ from D- on 9/24/2024 due to a decline in the volatility index.
D
Sell
9/9/2024Upgraded
Aligos Therapeutics, Inc. (ALGS) was upgraded to D- from E+ on 9/9/2024 due to an increase in the solvency index and volatility index.
Aligos Therapeutics, Inc. (ALGS) was upgraded to D- from E+ on 9/9/2024 due to an increase in the solvency index and volatility index.
E
Sell
6/10/2024Downgrade
Aligos Therapeutics, Inc. (ALGS) was downgraded to E+ from D- on 6/10/2024 due to a decline in the solvency index, volatility index and total return index. Debt to equity increased from 0.04 to 0.05.
Aligos Therapeutics, Inc. (ALGS) was downgraded to E+ from D- on 6/10/2024 due to a decline in the solvency index, volatility index and total return index. Debt to equity increased from 0.04 to 0.05.
D
Sell
4/11/2024Upgraded
Aligos Therapeutics, Inc. (ALGS) was upgraded to D- from E+ on 4/11/2024 due to an increase in the solvency index, total return index and volatility index. The quick ratio increased from 3.13 to 5.68, and debt to equity declined from 0.06 to 0.04.
Aligos Therapeutics, Inc. (ALGS) was upgraded to D- from E+ on 4/11/2024 due to an increase in the solvency index, total return index and volatility index. The quick ratio increased from 3.13 to 5.68, and debt to equity declined from 0.06 to 0.04.
E
Sell
7/31/2023Downgrade
Aligos Therapeutics, Inc. (ALGS) was downgraded to E+ from D- on 7/31/2023 due to a decline in the volatility index.
Aligos Therapeutics, Inc. (ALGS) was downgraded to E+ from D- on 7/31/2023 due to a decline in the volatility index.
D
Sell
7/14/2023Upgraded
Aligos Therapeutics, Inc. (ALGS) was upgraded to D- from E+ on 7/14/2023 due to an increase in the total return index and volatility index.
Aligos Therapeutics, Inc. (ALGS) was upgraded to D- from E+ on 7/14/2023 due to an increase in the total return index and volatility index.
E
Sell
6/27/2023Downgrade
Aligos Therapeutics, Inc. (ALGS) was downgraded to E+ from D- on 6/27/2023 due to a decline in the volatility index.
Aligos Therapeutics, Inc. (ALGS) was downgraded to E+ from D- on 6/27/2023 due to a decline in the volatility index.
D
Sell
6/12/2023Upgraded
Aligos Therapeutics, Inc. (ALGS) was upgraded to D- from E+ on 6/12/2023 due to an increase in the growth index and volatility index.
Aligos Therapeutics, Inc. (ALGS) was upgraded to D- from E+ on 6/12/2023 due to an increase in the growth index and volatility index.
E
Sell
3/14/2023Downgrade
Aligos Therapeutics, Inc. (ALGS) was downgraded to E+ from D on 3/14/2023 due to a decline in the growth index and volatility index. EBIT declined 19.71% from -$18.95M to -$22.68M, earnings per share declined from -$0.4355 to -$0.5109, and total revenue declined 13.86% from $4.11M to $3.54M.
Aligos Therapeutics, Inc. (ALGS) was downgraded to E+ from D on 3/14/2023 due to a decline in the growth index and volatility index. EBIT declined 19.71% from -$18.95M to -$22.68M, earnings per share declined from -$0.4355 to -$0.5109, and total revenue declined 13.86% from $4.11M to $3.54M.
D
Sell
2/23/2023Upgraded
Aligos Therapeutics, Inc. (ALGS) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
Aligos Therapeutics, Inc. (ALGS) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
D
Sell
2/8/2023Downgrade
Aligos Therapeutics, Inc. (ALGS) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index. Debt to equity increased from 0.02 to 0.03, and the quick ratio declined from 5.03 to 4.66.
Aligos Therapeutics, Inc. (ALGS) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index. Debt to equity increased from 0.02 to 0.03, and the quick ratio declined from 5.03 to 4.66.
D
Sell
9/12/2022Upgraded
Aligos Therapeutics, Inc. (ALGS) was upgraded to D from D- on 9/12/2022 due to an increase in the volatility index and total return index.
Aligos Therapeutics, Inc. (ALGS) was upgraded to D from D- on 9/12/2022 due to an increase in the volatility index and total return index.
D
Sell
8/26/2022Downgrade
Aligos Therapeutics, Inc. (ALGS) was downgraded to D- from D on 8/26/2022 due to a decline in the growth index and valuation index. Operating cash flow declined 22.52% from -$20.43M to -$25.04M.
Aligos Therapeutics, Inc. (ALGS) was downgraded to D- from D on 8/26/2022 due to a decline in the growth index and valuation index. Operating cash flow declined 22.52% from -$20.43M to -$25.04M.
D
Sell
5/16/2022Upgraded
Aligos Therapeutics, Inc. (ALGS) was upgraded to D from E+ on 05/16/2022.
Aligos Therapeutics, Inc. (ALGS) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
Aligos Therapeutics, Inc. (ALGS) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
Aligos Therapeutics, Inc. (ALGS) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
D
Sell
5/5/2022Upgraded
Aligos Therapeutics, Inc. (ALGS) was upgraded to D from E+ on 5/5/2022 due to a noticeable increase in the growth index and valuation index. Total revenue increased 600.54% from $367 to $2.57M, operating cash flow increased 45.48% from -$37.48M to -$20.43M, and EBIT increased 6.3% from -$37.95M to -$35.56M.
Aligos Therapeutics, Inc. (ALGS) was upgraded to D from E+ on 5/5/2022 due to a noticeable increase in the growth index and valuation index. Total revenue increased 600.54% from $367 to $2.57M, operating cash flow increased 45.48% from -$37.48M to -$20.43M, and EBIT increased 6.3% from -$37.95M to -$35.56M.
E
Sell
4/20/2022Downgrade
Aligos Therapeutics, Inc. (ALGS) was downgraded to E+ from D- on 4/20/2022 due to a noticeable decline in the solvency index, volatility index and total return index. Debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 6.96 to 4.9.
Aligos Therapeutics, Inc. (ALGS) was downgraded to E+ from D- on 4/20/2022 due to a noticeable decline in the solvency index, volatility index and total return index. Debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 6.96 to 4.9.
D
Sell
3/7/2022Downgrade
Aligos Therapeutics, Inc. (ALGS) was downgraded to D- from D on 3/7/2022 due to a decline in the total return index and volatility index.
Aligos Therapeutics, Inc. (ALGS) was downgraded to D- from D on 3/7/2022 due to a decline in the total return index and volatility index.
D
Sell
11/23/2021Upgraded
Aligos Therapeutics, Inc. (ALGS) was upgraded to D from D- on 11/23/2021.
Aligos Therapeutics, Inc. (ALGS) was upgraded to D from D- on 11/23/2021.
D
Sell
11/8/2021Downgrade
Aligos Therapeutics, Inc. (ALGS) was downgraded to D- from D on 11/8/2021 due to a decline in the volatility index, total return index and growth index. EBIT declined 11.85% from -$29.57M to -$33.07M, operating cash flow declined 10.21% from -$23.02M to -$25.37M, and total revenue declined 0.52% from $1.55M to $1.54M.
Aligos Therapeutics, Inc. (ALGS) was downgraded to D- from D on 11/8/2021 due to a decline in the volatility index, total return index and growth index. EBIT declined 11.85% from -$29.57M to -$33.07M, operating cash flow declined 10.21% from -$23.02M to -$25.37M, and total revenue declined 0.52% from $1.55M to $1.54M.
D
Sell
8/6/2021Downgrade
Aligos Therapeutics, Inc. (ALGS) was downgraded to D from D+ on 8/6/2021 due to a decline in the volatility index, valuation index and total return index.
Aligos Therapeutics, Inc. (ALGS) was downgraded to D from D+ on 8/6/2021 due to a decline in the volatility index, valuation index and total return index.
D
Sell
8/2/2021Upgraded
Aligos Therapeutics, Inc. (ALGS) was upgraded to D+ from D on 8/2/2021 due to an increase in the valuation index and total return index.
Aligos Therapeutics, Inc. (ALGS) was upgraded to D+ from D on 8/2/2021 due to an increase in the valuation index and total return index.
D
Sell
5/26/2021Downgrade
Aligos Therapeutics, Inc. (ALGS) was downgraded to D from D+ on 5/26/2021 due to a decline in the total return index and volatility index.
Aligos Therapeutics, Inc. (ALGS) was downgraded to D from D+ on 5/26/2021 due to a decline in the total return index and volatility index.
D
Sell
5/11/2021Upgraded
Aligos Therapeutics, Inc. (ALGS) was upgraded to D+ from D on 5/11/2021 due to a substantial increase in the solvency index, total return index and growth index. Earnings per share increased from -$1.0939 to -$0.74, EBIT increased 19.29% from -$34.37M to -$27.74M, and the quick ratio increased from 8.04 to 8.46.
Aligos Therapeutics, Inc. (ALGS) was upgraded to D+ from D on 5/11/2021 due to a substantial increase in the solvency index, total return index and growth index. Earnings per share increased from -$1.0939 to -$0.74, EBIT increased 19.29% from -$34.37M to -$27.74M, and the quick ratio increased from 8.04 to 8.46.
D
Sell
1/12/2021None
Aligos Therapeutics, Inc. (ALGS) was downgraded to D from U on 01/12/2021.
Aligos Therapeutics, Inc. (ALGS) was downgraded to D from U on 01/12/2021.
NASDAQ
04/04/2025 12:57PM Eastern
Quotes delayed
